Revolution Medicines
RVMD
200.87
+1.00
+0.50%
Revolution Medicines
US · RVMD
#499 by market cap
Listed 2020
200.87
+1.00
+0.50%
Live - 5344 symbols - heartbeat 515s ago
· 2026-10-08 07:27
Pre-market
198.00
-1.43%
After-hours
199.81
-0.53%
Overnight
199.95
-0.46%
- Market cap
- 43.05B
- P/E (TTM)i
- -22.65
- P/Bi
- 16.52
- EPSi
- -5.95
- Div yieldi
- 0.00%
- 52W posi
- 87%
Reader sentiment
Are you bullish or bearish on RVMD?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 22 analysts
Buy
Avg price target
261.75 +30.3%
Price target rangecurrent 200.87
Low210.00
Avg261.75
High320.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-28 | LifeSci Capital | -- | BUY | 315.00 |
| 2026-09-28 | Brookline Capital | -- | BUY | 318.00 |
| 2026-09-24 | Goldman Sachs | -- | BUY | 267.00 |
| 2026-09-21 | BofA Securities | -- | BUY | 265.00 |
| 2026-09-16 | RBC Capital | -- | BUY | 251.00 |
| 2026-09-14 | LifeSci Capital | -- | BUY | 315.00 |
| 2026-09-13 | Stifel | -- | BUY | 230.00 |
| 2026-09-10 | Morgan Stanley | -- | BUY | 255.00 |
| 2026-09-09 | Stifel | -- | BUY | 230.00 |
| 2026-09-03 | Truist Financial | -- | BUY | -- |
| 2026-09-03 | Jefferies | -- | BUY | 270.00 |
| 2026-09-02 | LifeSci Capital | -- | BUY | 315.00 |
| 2026-09-01 | J.P. Morgan | -- | BUY | 246.00 |
| 2026-08-31 | Needham | -- | BUY | 275.00 |
| 2026-08-29 | LifeSci Capital | -- | BUY | 315.00 |
| 2026-08-28 | UBS | -- | BUY | 265.00 |
| 2026-08-27 | Wells Fargo | -- | BUY | 240.00 |
| 2026-08-27 | Raymond James | -- | BUY | 248.00 |
| 2026-08-27 | Truist Financial | -- | BUY | 239.00 |
| 2026-08-27 | Wedbush | -- | BUY | 225.00 |
| 2026-08-27 | Jefferies | -- | BUY | 270.00 |
| 2026-08-27 | Evercore | -- | BUY | 320.00 |
| 2026-08-27 | Needham | -- | BUY | 240.00 |
| 2026-08-27 | Guggenheim | -- | BUY | 275.00 |
| 2026-08-27 | H.C. Wainwright | -- | BUY | 280.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | ±8.35% | +0.26% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±5.47% | -5.67% (beat) |
| 2025/Q4 | 2026-02-25 | After close | ±11.64% | -1.06% (in line) |
| 2025/Q3 | 2025-11-05 | After close | ±8.59% | +3.44% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±11.09% | -4.69% (in line) |
| 2025/Q1 | 2025-05-07 | After close | ±12.35% | +11.29% (in line) |
| 2024/Q4 | 2025-02-26 | After close | ±8.64% | -3.51% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±11.89% | -0.54% (in line) |
| 2024/Q2 | 2024-08-07 | After close | ±13.30% | -0.69% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±17.23% | -2.24% (in line) |
| 2023/Q4 | 2024-02-26 | After close | ±12.91% | +0.79% (in line) |
| 2023/Q3 | 2023-11-06 | After close | ±19.18% | -0.23% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:27:19 · For reference only, not investment advice and not tailored to your situation.